UNSPSC 51401703: Avizafone

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C22H27ClN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65NK71K78P, chemically known as 2-benzoyl-4-chloro-2-((s)-2,6-diaminohexanamido)-n-methylacetanilide but generally known as avizafone, which bears US NIH Compound Identifier 71968. European Medicines Agency schedules Avizafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05616MIG.

UNSPSC 51401703 Avizafone, a Commodity code, covers pharmaceutical products and drug-management systems that state and local governments procure to support public health, emergency response, and pharmacy benefit programs. State and local buyers under this code are acquiring naloxone (opioid overdose reversal medication), safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work spans product procurement with specific delivery and logistics requirements, direct-to-manufacturer contracting models designed to streamline pharmacy benefits, and multi-vendor supply arrangements through authorized wholesaler networks.

Recent activity shows concentrated procurement in Florida and Minnesota, with broader multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling state interest in alternative contracting models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026, requiring vendor participation through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with an effective contract date of July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight), cGMP certification, Drug Supply Chain Security Act compliance, and $5 million commercial general liability insurance.